Peroxisome Proliferator Activated Receptors: From Basic Science to Clinical Applications (Medical Science Symposia Series Book 18)

Peroxisome Proliferator Activated Receptors (PPARs) attract great attention in light of the wide spectrum of genes of biological and medical relevance identified as under their control. As a consequence, our knowledge of the role of these receptors in physiology and pathology continues to grow at a fast pace and PPARs have become an interesting target for the treatment of many pathological conditions, including diabetes and atherosclerosis. This volume provides an authoritative view of the current clinical and scientific developments within this evolving area of study. Front Matter....Pages i-xvi Peroxisome Proliferator Activated Receptor Alpha Coordinates Intermediary Metabolism During Fasting....Pages 1-4 Design, Structure, and Function of Novel PPAR Ligands....Pages 5-8 Functions of PPAR Gamma in Macrophages and Atherosclerosis....Pages 9-16 PPARs and Atherogenesis: Mediators or Modulators of the Inflammatory Response in the Vessel Wall?....Pages 17-24 Role of PPARs in Inflammation, Atherosclerosis, and Thrombosis....Pages 25-34 Effects of Thiazolidinediones on Vascular Reactivity and Endothelial Dysfunction....Pages 35-40 Activation of Human PPAR Subtypes by Pioglitazone....Pages 41-47 PPARγ Mechanism of Action Studies....Pages 49-53 The Role of PPARα in Fatty Acid Metabolism and Hepatocarcinogenesis: Studies with PPARα-Null Mice....Pages 55-62 PPARα, Lipoprotein Metabolism, Metabolic Diseases, and Atherosclerosis....Pages 63-79 PPARα and Atherosclerosis....Pages 81-87 Regulation of CD36 by PPARγ: Pro- or Antiatherogenic?....Pages 89-94 Anti-Inflammatory Properties of High Density Lipoproteins....Pages 95-101 The Low-HDL Syndrome: Epidemiology and Pathophysiology....Pages 103-108 Diabetes: A Growing CHD Epidemic....Pages 109-114 Influence of PPARs on Muscle Lipid Metabolism and Insulin Resistance....Pages 115-122 PPARγ in Adipogenesis and Insulin Resistance....Pages 123-130 Pharmacology of a Selective Peroxisome Proliferator-Activated Receptor δ Agonist, GW501516, in Obese Dyslipidemic Primates....Pages 131-134 PPARγ: A Regulator of Growth and Differentiation....Pages 135-141 Peroxisome Proliferator Activator Receptor Gamma Agonists Inhibit the Development of Atherosclerosis in Low Density Lipoprotein Receptor-Deficient Male Mice....Pages 143-148 Are Thiazolidinediones Superior to Standard Therapy in the Treatment of Type 2 Diabetes?....Pages 149-155 PParγ Ligands and Intestinal Inflammation....Pages 157-162 Inflammatory Mechanisms in Alzheimer’s Disease: β-Amyloid-Stimulated Proinflammatory Responses are Blocked by PPARγ Agonists....Pages 163-168 Back Matter....Pages 169-172